Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Background Given the unique phenotype of type 2 diabetes in Japanese patients, novel therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed to assess the dose-response of oral semaglutide and to compare the efficacy and safety of oral semaglutide with placebo and a subcutaneous GLP-1 receptor agonist in a Japanese population.Methods PIONEER 9 was a 52-week, phase 2/3a, randomised, controlled trial done at 16 sites (clinics and university hospitals) in Japan. Japanese patients aged 20 years or older with uncontrolled type 2 diabetes managed by diet or exercise or with oral glucose-lowering drug monotherapy (washed out) were randomly assigned (1:1:1:1:1) to receive double-blind once-daily oral semaglutide (3 mg, 7 mg, or 14 mg) or placebo, or open-label subcutaneous once-daily liraglutide 0·9 mg. The primary endpoint was change in HbA 1c from baseline to week 26 with the trial product (primary) estimand (which assumes all patients remained on trial product without rescue medication use) in all randomly assigned patients. This trial is registered with ClinicalTrials.gov, NCT03018028.Findings Between Jan 10, and July 11, 2017, 243 patients were randomly assigned to oral semaglutide 3 mg (n=49), 7 mg (n=49), or 14 mg (n=48), or placebo (n=49), or to liraglutide 0·9 mg (n=48). Changes in HbA 1c from baseline (mean 8·2%) to week 26 were dose-dependent with oral semaglutide (mean change -1·1% [SE 0·1] for oral semaglutide 3 mg, -1·5% [0·1] for 7 mg, and -1·7% [0·1] for 14 mg), -0·1% (0·1) with placebo, and -1·4% (0·1) with liraglutide 0·9 mg. Estimated treatment differences for change in HbA 1c compared with placebo were -1·1 percentage points (95% CI -1·4 to -0·8; p<0·0001) for oral semaglutide 3 mg, -1·5 percentage points (-1·7 to -1·2; p<0·0001) for oral semaglutide 7 mg, and -1·7 percentage points (-2·0 to -1·4; p<0·0001) for oral semaglutide 14 mg. Estimated treatment differences for change in HbA 1c compared with liraglutide 0·9 mg were 0·3 percentage points (95% CI -0·0 to 0·6; p=0·0799) for oral semaglutide 3 mg, -0·1 percentage points (-0·4 to 0·2; p=0·3942) for oral semaglutide 7 mg, and -0·3 percentage points (-0·6 to -0·0; p=0·0272) for oral semaglutide 14 mg. Gastrointestinal events, predominantly of mild or moderate severity, were the most frequently reported class of adverse event with oral semaglutide: constipation was most common, occurring in five to six (10-13%) patients with oral semaglutide, three (6%) with placebo, and nine (19%) with liraglutide 0·9 mg.Interpretation This study showed that oral semaglutide provides significant reductions in HbA 1c compared with placebo in a dose-dependent manner in Japanese patients with type 2 diabetes, and has a safety profile consistent with that of GLP-1 receptor agonists.Funding Novo Nordisk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk.”
In the citing paper
“Significant reductions in HbA1c were reported, ranging from −0.2% in the study by Buse et al. [24] with a flexible dose of oral semaglutide, to −1.7% for the 14 mg dose in the study by Yamada et al. [32]”
In the citing paper
“In other phase 3 trials, no increase in hypoglycemia risk was observed versus comparator groups, including other GLP-1RAs (18–21, 23, 33–36).”
From Safety of Semaglutide (2021) · cites this paper as [23]
In the citing paper
“In the PIONEER program, four thyroid malignancies occurred in semaglutide-treated patients, versus one in the comparator group”
From Safety of Semaglutide (2021) · cites this paper as [23]
In the citing paper
“In PIONEER-9, oral semaglutide induced nausea in up to 10% of patients, whereas none of the liraglutide patients had nausea”
From Safety of Semaglutide (2021) · cites this paper as [23]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Statistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Self-citationNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Cited by
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 240
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Self-citation
Metadata
- Authors
- Yamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., Ide, Y., Inoue, S., Kawada, T., Kim, H., Kiyosue, A., Matoba, K., Matsuoka, O., Nishimura, H., Noguchi, M., Osonoi, T., Sawada, S., Shibasaki, Y., Shin, K., & Yamada, Y.
- Affiliations
- Tohoku University (JP)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Pharma Ltd. (Japan) (JP)
- Kansai Electric Power (Japan) (JP)
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 8
- Issue
- 5
- Pages
- 377-391
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3017978130
- Cited by
- 228
- References
- 32
- Citations by year
- 2026: 21 · 2025: 49 · 2024: 48 · 2023: 27 · 2022: 33 · 2021: 24 · 2020: 26
- FWCI
- 20.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, Japanese patients, dose-response relationship, HbA1c, liraglutide, GLP-1 receptor agonists, monotherapy, glycemic control, drug safety, adverse events, oral versus subcutaneous administration, uncontrolled diabetes, oral glucose-lowering agents
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adult, Aged, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30075-9
- The paper
- Yamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., Ide, Y., Inoue, S., Kawada, T., Kim, H., Kiyosue, A., Matoba, K., Matsuoka, O., Nishimura, H., Noguchi, M., . . . Yamada, Y. (2020). Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30075-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.